-CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, with the European Medicines...
Non-executive director to bring extensive life science industry and finance experience SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE)...
WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for...
BOTHELL, Wash., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has...
TORONTO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company...
U.S. Food and Drug Administration (FDA) Cleared Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical...
MINNEAPOLIS, MN, US, Aug. 08, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device...
Presented Additional Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Utility in...
SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for...
BOCA RATON, Fla., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),...
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty...
Conference call to be held today, August 8, 2022 at 8:30 AM ETNEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) --...
New York, NY, and Tel Aviv, ISRAEL, Aug. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive...
Positive topline data in the Phase 2 BrigHtn trial, demonstrating clinically meaningful and statistically significant reduction in blood pressure with...
~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington’s disease showed the investigative gene therapy was generally...
98% of 401 Primary Care Physicians confirmed KidneyIntelX has value as a risk decision tool in their adult patients with...
Successfully met the primary endpoint in the BrigHtn trial, delivering a 20.3 mmHg reduction in systolic blood pressure (SBP), or...
Progressive Care Inc. PharmcoRx Pharmacy Logo 2022MIAMI, FL, Aug. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Progressive Care Inc....
SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve...
The Celebration Comes Just as Over 8,000 People Complete the Be There Certificate, a Free Online Course For Peer-to-Peer Mental...